Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease

Inclusion Criteria: * Adults between 18 and 60 years of age, both men and women, * Clinical diagnosis of NAFLD, confirmed by imaging exams, * Patients who present levels above the reference values of ALT, AST and ferritin. Exclusion Criteria: * Women in the menacing period, with the exception of those who have performed definitive sterilization, such as hysterectomy or tubal ligation. * Patients with established prior diagnosis of chronic noncommunicable disease (congestive heart failure, decompensated or severe lung disease, neoplasms, renal disease, advanced liver disease - Child Pugh C classification) * Patients with schistosomiasis; * Hemochromatosis * Wilson's disease * Viral or autoimmune hepatitis * HIV virus carriers * Woman who is breastfeeding * Users of illicit drugs * Patients with an intake of more than 20 g / day of alcohol and / or past alcoholism with abstention less than 6 months; * Patients with ingestion of medications such as steroids, estrogens, amiodarone, warfarin, anti-convulsants, antipsychotics, tamoxifen or other chemotherapeutic agents in the last 6 months * Patients with clinically manifest infections or inflammation, surgery, trauma or hospitalization in the last 30 days * Chronic non-hepatic degenerative diseases (sclerosis, Parkinson's disease or -Alzheimer's disease) * Patients who do not participate in all stages of the research.